"Warning of the attempt
Guidelines for implementation of article 13 (tobacco advertising, promotion and sponsorship)

More specifically, we reviewed current drugs used in the clinic, including chemotherapy (RO4929097 plus erlotinib, sulforaphane plus cisplatin and doxorubicin, AKBA plus cisplatin), targeted therapy (gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, crizotinib, lorlatinib, alectinib, ceritinib, brigatinib, dabrafenib plus trametinib, larotrectinib, entrectinib, pralsetinib, selpercatinib, pyrotinib, tucatinib, trastuzumab, trastuzumab deruxtecan, adagrasib, sotorasib, DPT plus gefitinib, osimertinib plus dacomitinib, osimertinib, and navitoclax), antiangiogenic therapy (bevacizumab, FKB238, LY01008), immunotherapy (ipilimumab, pembrolizumab, atezolizumab, nivolumab, durvalumab, avelumab, sugemalimab, toripalimab, nivolumab plus ipilimumab, durvalumab plus tremelimumab, avelumab plus pepinemab), combination therapy, such as chemoradiotherapy plus immunotherapy (conventional chemoradiotherapy (platinum-based chemotherapy add radiotherapy) plus durvalumab, toripalimab plus platinum-based doublet chemotherapy, camrelizumab plus chemotherapy such as carboplatin and paclitaxel, camrelizumab and chemotherapy including carboplatin and pemetrexed), targeted therapy plus antiangiogenic therapy (erlotinib plus bevacizumab, gefitinib plus apatinib), antiangiogenic therapy plus chemotherapy (bevacizumab plus carboplatin and paclitaxel, bevacizumab plus cisplatin and gemcitabine), antiangiogenic therapy plus immunotherapy (bevacizumab and atezolizumab, anlotinib plus camrelizumab), antiangiogenic therapy plus immunotherapy and chemotherapy (bevacizumab combined with atezolizumab and chemotherapy (carboplatin and paclitaxel)), and immunotherapy plus radiotherapy (pembrolizumab plus radiotherapy, durvalumab and/or tremelimumab plus radiotherapy)

However, for the most part, Dyson kept all the packaging for the Purifier Hot + Cool HP1 recyclable